Trial Review

The ANZCTR website is back online for trial registration and updates. We apologise for any inconvenience caused while the site was inactive.


With activity expected to increase on the ANZCTR again, there may be extended wait times while we process pending studies, with priority being given to those trials submitted in February. Thank you for your patience.


Reset your password and enable multi-factor authentication (MFA)


For ANZCTR account holders: to help ensure the cyber safety of your account, you’ll need to reset your password and set-up multi-factor authentication (MFA) as per the instructions below.


  1. Go to the Login page, click ‘reset password’ and follow the instructions.
  2. Check your email for the link to set a new password.
  3. Create a new password that meets requirements.
  4. Return to the Login page and enter your new password. A verification code will be sent to your email.
  5. Check your email for the code and enter it on the Login page. If the code is entered incorrectly, you can re-enter the correct one or request a new one.

Learn more about MFA and its importance on the Australian Signals Directorate website.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00100802




Registration number
NCT00100802
Ethics application status
Date submitted
6/01/2005
Date registered
7/01/2005
Date last updated
15/02/2023

Titles & IDs
Public title
Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas
Scientific title
A Phase II Study of Concurrent Radiation and Temozolomide Followed By Temozolomide and CCNU in the Treatment of Children With High-Grade Glioma
Secondary ID [1] 0 0
NCI-2012-02645
Secondary ID [2] 0 0
ACNS0423
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Anaplastic Astrocytoma 0 0
Central Nervous System Neoplasm 0 0
Glioblastoma 0 0
Gliosarcoma 0 0
Spinal Cord Neoplasm 0 0
Condition category
Condition code
Cancer 0 0 0 0
Brain
Cancer 0 0 0 0
Children's - Brain
Cancer 0 0 0 0
Neuroendocrine tumour (NET)
Cancer 0 0 0 0
Other cancer types

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - Laboratory Biomarker Analysis
Treatment: Drugs - Lomustine
Treatment: Other - Radiation Therapy
Treatment: Drugs - Temozolomide

Experimental: Treatment (lomustine, temozolomide, radiation therapy) - Patients receive oral temozolomide once daily on days 1-42. Patients also undergo concurrent radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33 and 36-40. Patients who did not undergo prior gross total resection also undergo boost radiotherapy once daily on days 43-47. Four weeks after completion of chemoradiotherapy, patients receive oral temozolomide once daily on days 1-5 and oral lomustine on day 1. Treatment repeats every 42 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.


Other interventions: Laboratory Biomarker Analysis
Correlative studies

Treatment: Drugs: Lomustine
Given PO

Treatment: Other: Radiation Therapy
Undergo radiation therapy

Treatment: Drugs: Temozolomide
Given PO
Intervention code [1] 0 0
Other interventions
Intervention code [2] 0 0
Treatment: Drugs
Intervention code [3] 0 0
Treatment: Other
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
One Year Overall Survival
Timepoint [1] 0 0
One year
Primary outcome [2] 0 0
Occurrence of Death Attributable to Complications of Protocol Therapy
Timepoint [2] 0 0
While receiving protocol therapy (up to 301 days excluding delays) or within 30 days of Termination of Protocol Therapy

Eligibility
Key inclusion criteria
* Histologically confirmed, newly diagnosed high-grade glioma of 1 of the following histologies:

* Anaplastic astrocytoma
* Glioblastoma multiforme
* Gliosarcoma
* Primary spinal cord malignant gliomas allowed
* No primary brainstem tumors
* Has undergone surgical resection or biopsy of the tumor within the past 31 days

* Pre-operative and post-operative brain MRI with and without gadolinium-contrast OR pre-operative and post-operative spine MRI for spinal cord primaries

* Post-operative MRI not required for patients who undergo biopsy only
* No evidence of neuraxis dissemination

* Spine MRI and cerebrospinal fluid cytology required only if clinically indicated
* Performance status - Karnofsky 50-100% (for patients > 16 years of age)
* Performance status - Lansky 50-100% (for patients = 16 years of age)
* At least 8 weeks
* Absolute neutrophil count = 1,000/mm^3
* Platelet count = 100,000/mm^3 (transfusion independent)
* Hemoglobin = 8 g/dL (transfusions allowed)
* Bilirubin = 1.5 times upper limit of normal (ULN)
* ALT = 2.5 times ULN
* Albumin = 2 g/dL
* Creatinine = 1.5 times ULN
* Creatinine clearance or radioisotope glomerular filtration rate = lower limit of normal
* No evidence of dyspnea at rest
* No exercise intolerance
* Pulse oximetry = 94% (if determination is clinically indicated)
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception during and for 2 months after study participation
* Able to swallow oral medication
* Seizures allowed provided they are well controlled with anticonvulsants
* No hypersensitivity to temozolomide
* No prior biologic agents
* No prior chemotherapy
* Prior corticosteroids allowed
* No concurrent corticosteroids as an antiemetic
* Concurrent corticosteroids allowed only for treatment of increased intracranial pressure
* No concurrent radiotherapy using cobalt-60
* See Disease Characteristics
* No other prior treatment
* No concurrent phenobarbital or cimetidine
* No concurrent co-trimoxazole for Pneumocystis carinii pneumonia prophylaxis during study chemoradiotherapy
Minimum age
3 Years
Maximum age
21 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria

Study design
Purpose of the study
Treatment
Allocation to intervention
Not applicable
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
21/03/2005
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
30/06/2017
Sample size
Target
Accrual to date
Final
118
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Pennsylvania

Funding & Sponsors
Primary sponsor type
Other
Name
Children's Oncology Group
Address
Country
Other collaborator category [1] 0 0
Government body
Name [1] 0 0
National Cancer Institute (NCI)
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Regina I Jakacki
Address 0 0
Children's Oncology Group
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

TypeCitations or Other Details
Journal Pollack IF, Hamilton RL, Sobol RW, Nikiforova MN, ... [More Details]

Results are available at https://clinicaltrials.gov/study/NCT00100802